Analysts Expect Insulet Co. (NASDAQ:PODD) Will Post Quarterly Sales of $270.85 Million

Analysts expect Insulet Co. (NASDAQ:PODD) to post $270.85 million in sales for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Insulet’s earnings. The highest sales estimate is $275.68 million and the lowest is $266.20 million. Insulet posted sales of $234.00 million during the same quarter last year, which suggests a positive year over year growth rate of 15.7%. The company is scheduled to report its next earnings results on Wednesday, November 3rd.

On average, analysts expect that Insulet will report full year sales of $1.08 billion for the current financial year, with estimates ranging from $1.07 billion to $1.09 billion. For the next fiscal year, analysts anticipate that the business will post sales of $1.29 billion, with estimates ranging from $1.25 billion to $1.32 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Insulet.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 5th. The medical instruments supplier reported $0.10 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.12 by ($0.02). Insulet had a negative net margin of 3.06% and a positive return on equity of 0.21%. The firm had revenue of $263.20 million for the quarter, compared to analyst estimates of $257.80 million.

Several brokerages recently weighed in on PODD. TheStreet cut shares of Insulet from a “b” rating to a “c+” rating in a research note on Friday, May 28th. Canaccord Genuity upped their target price on Insulet from $280.00 to $300.00 and gave the company a “buy” rating in a report on Friday, August 6th. Citigroup raised their price target on shares of Insulet from $310.00 to $325.00 and gave the stock a “buy” rating in a report on Friday, August 6th. Cowen upped their price target on shares of Insulet from $285.00 to $310.00 and gave the company an “outperform” rating in a research report on Wednesday, July 21st. Finally, SVB Leerink dropped their target price on shares of Insulet from $325.00 to $300.00 and set an “outperform” rating on the stock in a research report on Friday, August 6th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet has a consensus rating of “Buy” and a consensus target price of $282.31.

Shares of NASDAQ:PODD traded down $1.40 during midday trading on Friday, hitting $289.20. 177,531 shares of the stock were exchanged, compared to its average volume of 453,356. The business’s 50-day moving average price is $287.64 and its 200 day moving average price is $276.11. Insulet has a 12 month low of $214.21 and a 12 month high of $309.99. The company has a debt-to-equity ratio of 2.69, a quick ratio of 4.95 and a current ratio of 5.87. The stock has a market capitalization of $19.92 billion, a price-to-earnings ratio of -631.43 and a beta of 0.67.

In other Insulet news, EVP Bret Christensen sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, August 26th. The stock was sold at an average price of $294.13, for a total transaction of $882,390.00. Following the completion of the sale, the executive vice president now directly owns 16,331 shares of the company’s stock, valued at approximately $4,803,437.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.00% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC boosted its holdings in Insulet by 54.8% during the first quarter. Commonwealth Equity Services LLC now owns 9,525 shares of the medical instruments supplier’s stock worth $2,485,000 after purchasing an additional 3,371 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Insulet by 26.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 36,359 shares of the medical instruments supplier’s stock worth $9,487,000 after buying an additional 7,593 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Insulet by 4.0% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,388 shares of the medical instruments supplier’s stock worth $3,493,000 after buying an additional 520 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new position in shares of Insulet in the first quarter valued at approximately $379,000. Finally, Arizona State Retirement System increased its position in shares of Insulet by 1.0% during the first quarter. Arizona State Retirement System now owns 19,009 shares of the medical instruments supplier’s stock valued at $4,960,000 after acquiring an additional 184 shares during the last quarter. Hedge funds and other institutional investors own 99.99% of the company’s stock.

Insulet Company Profile

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.

Recommended Story: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.